Furthermore, ASS1 is associated with chemoresistance, invasion, recurrence, and poor clinical outcomes, including breast cancer, HCC, renal cell carcinoma, and prostate cancer [10, 13, 14], in which ASS1 expression is lost [8, 10, 11]. This evidence concerns the gene ASS1 and prostate carcinoma.